Ken Griffin Otonomy, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$1.72 - $2.51 $29,449 - $42,976
17,122 Added 89.94%
36,160 $75,000
Q1 2022

May 16, 2022
SELL
$1.72 - $2.47 $88,203 - $126,664
-51,281 Reduced 72.93%
19,038 $46,000
Q2 2021

Aug 16, 2021
BUY
$2.06 - $2.67 $45,639 - $59,153
22,155 Added 46.0%
70,319 $156,000
Q1 2021

May 17, 2021
SELL
$2.49 - $6.23 $2.89 Million - $7.22 Million
-1,158,850 Reduced 96.01%
48,164 $123,000
Q4 2020

Feb 16, 2021
SELL
$3.48 - $6.47 $58,933 - $109,569
-16,935 Reduced 1.38%
1,207,014 $7.81 Million
Q3 2020

Nov 16, 2020
BUY
$3.16 - $4.36 $3.82 Million - $5.27 Million
1,207,847 Added 7501.22%
1,223,949 $4.96 Million
Q2 2020

Aug 14, 2020
SELL
$1.87 - $3.84 $51,174 - $105,085
-27,366 Reduced 62.96%
16,102 $58,000
Q1 2020

May 15, 2020
BUY
$1.58 - $4.06 $47,393 - $121,783
29,996 Added 222.65%
43,468 $85,000
Q4 2019

Feb 14, 2020
BUY
$2.13 - $3.83 $4,847 - $8,717
2,276 Added 20.33%
13,472 $52,000
Q2 2019

Aug 14, 2019
SELL
$2.35 - $3.09 $9,383 - $12,338
-3,993 Reduced 26.29%
11,196 $31,000
Q1 2019

May 15, 2019
SELL
$1.8 - $2.97 $79,900 - $131,835
-44,389 Reduced 74.51%
15,189 $0
Q3 2018

Nov 13, 2018
SELL
$2.6 - $3.95 $9,300 - $14,129
-3,577 Reduced 5.66%
59,578 $0
Q2 2018

Aug 10, 2018
SELL
$3.7 - $4.75 $139,049 - $178,509
-37,581 Reduced 37.31%
63,155 $0
Q1 2018

May 11, 2018
BUY
$4.05 - $6.1 $52,273 - $78,732
12,907 Added 14.7%
100,736 $423,000
Q4 2017

Feb 09, 2018
SELL
$2.8 - $5.55 $1.09 Million - $2.15 Million
-388,150 Reduced 81.55%
87,829 $487,000
Q3 2017

Nov 09, 2017
BUY
$3.2 - $20.8 $1.52 Million - $9.9 Million
475,979
475,979 $1.55 Million

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email